Literature DB >> 18193357

Progress in the development of prognostic and predictive markers for gastrointestinal malignancies.

Crystal S Denlinger1, Steven J Cohen.   

Abstract

Gastrointestinal cancers remain a significant cause of morbidity and mortality. While increasing therapeutic options have improved outcomes for many patients, they have also complicated treatment decision-making. Unfortunately, most patients with advanced gastrointestinal malignancies die from their disease. Prognostic and predictive markers could improve treatment significantly by identifying patients who may or may not require a given therapy, and determining those most likely to benefit from a therapy. Candidates for such markers include blood antigens and circulating tumor cells, tumor enzyme and gene expression, and pharmacodynamic endpoints. In this review, we summarize reported and ongoing research to define and validate prognostic and predictive markers in gastrointestinal malignancies, with an emphasis on colorectal cancer and brief overview of pancreatic and neuroendocrine tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18193357     DOI: 10.1007/s11864-007-0045-x

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  78 in total

1.  A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer.

Authors:  S Popat; Z Chen; D Zhao; H Pan; N Hearle; I Chandler; Y Shao; W Aherne; Rs Houlston
Journal:  Ann Oncol       Date:  2006-09-13       Impact factor: 32.976

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  Detection of carcinoembryonic antigen messenger RNA-expressing cells in peripheral blood 7 days after curative surgery is a novel prognostic factor in colorectal cancer.

Authors:  Sotaro Sadahiro; Toshiyuki Suzuki; Yuji Maeda; Satoshi Yurimoto; Seiei Yasuda; Hiroyasu Makuuchi; Akemi Kamijo; Chieko Murayama
Journal:  Ann Surg Oncol       Date:  2007-01-03       Impact factor: 5.344

4.  Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.

Authors:  Christiane Jakob; Torsten Liersch; Wolfdietrich Meyer; Gustavo B Baretton; Wolfgang Schwabe; Peter Häusler; Bettina Kulle; Heinz Becker; Daniela E Aust
Journal:  Am J Surg Pathol       Date:  2006-09       Impact factor: 6.394

5.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Authors:  Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz
Journal:  J Clin Oncol       Date:  2001-12-01       Impact factor: 44.544

6.  Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors.

Authors:  Y J Park; E G Youk; H S Choi; S U Han; K J Park; K U Lee; K J Choe; J G Park
Journal:  Int J Colorectal Dis       Date:  1999-04       Impact factor: 2.571

7.  Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels.

Authors:  Jaw-Yuan Wang; Shiu-Ru Lin; Deng-Chyang Wu; Chien-Yu Lu; Fang-Jung Yu; Jan-Sing Hsieh; Tian-Lu Cheng; Lok-Beng Koay; Yih-Huei Uen
Journal:  Clin Cancer Res       Date:  2007-04-03       Impact factor: 12.531

8.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Authors:  Elisa Giovannetti; Mario Del Tacca; Valentina Mey; Niccola Funel; Sara Nannizzi; Sergio Ricci; Cinzia Orlandini; Ugo Boggi; Daniela Campani; Marco Del Chiaro; Mauro Iannopollo; Generoso Bevilacqua; Franco Mosca; Romano Danesi
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

9.  Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.

Authors:  Ruth Birbe; Juan P Palazzo; Rhonda Walters; David Weinberg; Stephanie Schulz; Scott A Waldman
Journal:  Hum Pathol       Date:  2005-02       Impact factor: 3.466

10.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.

Authors:  Y Nakano; S Tanno; K Koizumi; T Nishikawa; K Nakamura; M Minoguchi; T Izawa; Y Mizukami; T Okumura; Y Kohgo
Journal:  Br J Cancer       Date:  2007-01-16       Impact factor: 7.640

View more
  3 in total

1.  Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients.

Authors:  Gennaro Galizia; Marica Gemei; Michele Orditura; Ciro Romano; Anna Zamboli; Paolo Castellano; Andrea Mabilia; Annamaria Auricchio; Ferdinando De Vita; Luigi Del Vecchio; Eva Lieto
Journal:  J Gastrointest Surg       Date:  2013-06-28       Impact factor: 3.452

2.  Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.

Authors:  Lauren E Colbert; Sarah B Fisher; Claire W Hardy; William A Hall; Burcu Saka; Joseph W Shelton; Aleksandra V Petrova; Matthew D Warren; Brooke G Pantazides; Khanjan Gandhi; Jeanne Kowalski; David A Kooby; Bassel F El-Rayes; Charles A Staley; N Volkan Adsay; Walter J Curran; Jerome C Landry; Shishir K Maithel; David S Yu
Journal:  Cancer       Date:  2013-05-29       Impact factor: 6.860

3.  The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.

Authors:  Yong-Ping Liu; Yang Ling; Qiu-Feng Qi; Ya-Ping Zhang; Chang-Song Zhang; Chang-Tai Zhu; Mei-Hua Wang; Yao-Dong Pan
Journal:  Oncol Lett       Date:  2012-12-28       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.